| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $57,970,728 | 34 | 100 |
| Denton Sheila A. | EVP & General Counsel | 0 | $0 | 2 | $89,625 | $-89,625 |
| Heeson Lee | EVP, Head of Incyte Intl | 0 | $0 | 1 | $289,017 | $-289,017 |
| Tray Thomas | Principal Accounting Officer | 0 | $0 | 6 | $878,953 | $-878,953 |
| Issa Mohamed Khairie | EVP, Head of US Oncology | 0 | $0 | 2 | $1.31M | $-1.31M |
| Clancy Paul J | director | 0 | $0 | 1 | $1.42M | $-1.42M |
| Morrissey Michael James | EVP, Head of Tech. Operations | 0 | $0 | 2 | $5.68M | $-5.68M |
| Mayes Patrick A | EVP & Chief Scientific Officer | 0 | $0 | 5 | $6.56M | $-6.56M |
| Stein Steven H | EVP & Chief Medical Officer | 0 | $0 | 6 | $7.86M | $-7.86M |
| CAGNONI PABLO J | President, R&D | 0 | $0 | 9 | $14.4M | $-14.4M |
| Hoppenot Herve | director | 0 | $0 | 1 | $19.77M | $-19.77M |
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's …
Over the last 12 months, insiders at Incyte Corporation have bought $0 and sold $57.97M worth of Incyte Corporation stock.
On average, over the past 5 years, insiders at Incyte Corporation have bought $258.25M and sold $16.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 84 shares for transaction amount of $6,044 was made by BAKER FELIX () on 2022‑03‑08.
| 2026-10-15 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 2,642 0.0013% | $112.71 | $297,780 | +2.95% | |
| 2026-09-15 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 23,218 0.0113% | $120.49 | $2.8M | -4.06% | |
| 2026-08-19 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 10,801 0.0052% | $125.56 | $1.36M | -5.24% | |
| 2026-08-12 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 10,803 0.0053% | $120.04 | $1.3M | +0.99% | |
| 2026-08-05 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 10,640 0.0054% | $122.69 | $1.31M | +1.39% | |
| 2026-08-05 | Sale | Mayes Patrick A | EVP & Chief Scientific Officer | 2,207 0.0011% | $123.99 | $273,646 | +1.39% | |
| 2026-08-03 | Sale | Mayes Patrick A | EVP & Chief Scientific Officer | 6,055 0.0031% | $120.43 | $729,204 | +2.47% | |
| 2026-07-31 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 15,888 0.0079% | $119.70 | $1.9M | +1.41% | |
| 2026-07-31 | Sale | Mayes Patrick A | EVP & Chief Scientific Officer | 41,899 0.0209% | $119.46 | $5.01M | +1.41% | |
| 2026-07-16 | Sale | Issa Mohamed Khairie | EVP, Head of U.S. Commercial | 1,093 0.0005% | $115.01 | $125,706 | +3.39% | |
| 2026-07-16 | Sale | Stein Steven H | CMO & Head of Late-Stage Dev. | 1,877 0.0009% | $114.73 | $215,348 | +3.39% | |
| 2026-07-15 | Sale | Stein Steven H | CMO & Head of Late-Stage Dev. | 28,237 0.0139% | $113.05 | $3.19M | +4.77% | |
| 2026-06-04 | Sale | Tray Thomas | Principal Accounting Officer | 2,639 0.0013% | $100.00 | $263,900 | +16.15% | |
| 2026-05-26 | Sale | Tray Thomas | Principal Accounting Officer | 2,051 0.001% | $97.35 | $199,665 | +20.70% | |
| 2026-05-19 | Sale | Clancy Paul J | director | 15,000 0.0075% | $94.93 | $1.42M | +22.28% | |
| 2026-04-17 | Sale | CAGNONI PABLO J | President, Global Head of R&D | 18,667 0.0093% | $96.50 | $1.8M | +18.21% | |
| 2026-03-17 | Sale | CAGNONI PABLO J | President, R&D | 18,667 0.0094% | $94.24 | $1.76M | +20.36% | |
| 2026-02-19 | Sale | CAGNONI PABLO J | President, R&D | 18,668 0.0092% | $100.91 | $1.88M | +9.57% | |
| 2026-01-07 | Sale | Issa Mohamed Khairie | EVP, Head of US Oncology | 10,856 0.0054% | $109.07 | $1.18M | -4.82% | |
| 2026-01-05 | Sale | Stein Steven H | EVP & Chief Medical Officer | 15,634 0.008% | $101.70 | $1.59M | +3.54% |
| Hoppenot Herve | director | 329646 0.1617% | $38.76M | 2 | 4 | +4.34% |
| BAKER BROS. ADVISORS LP | 33039604 16.2092% | $3.89B | 11 | 0 | +3.8% | |
| BAKER JULIAN | director | 19757285 9.6929% | $2.32B | 8 | 0 | +17.75% |
| Baker Brothers Life Sciences Capital (GP), LLC | director, 10 percent owner | 12430783 6.0985% | $1.46B | 51 | 5 | +21.96% |
| Baker Biotech Capital (GP), LLC | director, 10 percent owner | 2933021 1.4389% | $344.89M | 43 | 5 | +21.05% |
| BAKER FELIX | 2926657 1.4358% | $344.15M | 1 | 0 | +8.15% | |
| TISCH THOMAS J | other | 1416661 0.695% | $166.59M | 1 | 0 | +52.29% |
| TISCH ANDREW H | other | 1216661 0.5969% | $143.07M | 1 | 0 | +52.29% |
| TISCH JAMES S | other | 1216661 0.5969% | $143.07M | 1 | 0 | +52.29% |
| TISCH DANIEL R | other | 1216661 0.5969% | $143.07M | 1 | 0 | +52.29% |
| BAKER BIOTECH CAPITAL II GP LLC | 10 percent owner | 1091407 0.5354% | $128.34M | 2 | 0 | +39.59% |
| 14159 capital (GP), LLC | director, 10 percent owner | 355839 0.1746% | $41.84M | 50 | 5 | +21.76% |
| FRIEDMAN PAUL A | director | 255531 0.1254% | $30.05M | 12 | 20 | +76.59% |
| Baker Bros. Capital (GP), LLC | director, 10 percent owner | 239258 0.1174% | $28.13M | 42 | 5 | +21.44% |
| BROOKE PAUL A | director | 196756 0.0965% | $23.14M | 3 | 2 | +3.81% |
| Baker / Tisch Capital (GP), LLC | director, 10 percent owner | 159739 0.0784% | $18.78M | 29 | 5 | +15.27% |
| DE SCHUTTER RICHARD U | director | 92290 0.0453% | $10.85M | 2 | 6 | +19.56% |
| SWAIN PAULA J | EVP, Human Resources | 77530 0.038% | $9.12M | 1 | 39 | +27.11% |
| METCALF BRIAN W | Chief Drug Discovery Scientist | 66504 0.0326% | $7.82M | 2 | 4 | +24.57% |
| DIXON WENDY L | director | 17259 0.0085% | $2.03M | 1 | 5 | +44.82% |
| BIENAIME JEAN JACQUES | director | 8646 0.0042% | $1.02M | 6 | 3 | <0.0001% |
| HASTINGS DAVID C | Chief Financial Officer | 8500 0.0042% | $999,515.00 | 3 | 8 | +39.74% |
| SCHRECK PATRICIA A | EVP, General Counsel | 4500 0.0022% | $529,155.00 | 2 | 4 | +35.88% |
| Chardonnet Laurent | 2905 0.0014% | $341,598.95 | 1 | 13 | +38.15% |
Incyte Corporation (INCY) | $961,890,236 | 276 | 22.46% | $23.97B |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$2,449,191,716 | 58 | 16.50% | $100.2B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 519 | +78.64% | 16M | +8.12% |
| Decreased Positions | 289 | -43.79% | 14M | -6.76% |
| New Positions | 172 | New | 2M | New |
| Sold Out Positions | 52 | Sold Out | 2M | Sold Out |
| Total Postitions | 890 | +34.85% | 203M | +1.37% |
| Baker Bros. Advisors Lp | $3.12M | 15.69% | 30.74M | +388 | +<0.01% | 2025-09-30 |
| Vanguard Group Inc | $2.02M | 10.18% | 19.95M | -183,770 | -0.91% | 2025-09-30 |
| Blackrock, Inc. | $1.81M | 9.13% | 17.89M | -62,511 | -0.35% | 2025-09-30 |
| Dodge & Cox | $1.41M | 7.11% | 13.93M | -662,765 | -4.54% | 2025-09-30 |
| State Street Corp | $981,421.00 | 4.94% | 9.68M | -198,962 | -2.02% | 2025-09-30 |
| Aqr Capital Management Llc | $803,602.00 | 4.04% | 7.92M | -277,944 | -3.39% | 2025-09-30 |
| Renaissance Technologies Llc | $459,243.00 | 2.31% | 4.53M | +646,200 | +16.65% | 2025-09-30 |
| Geode Capital Management, Llc | $454,987.00 | 2.29% | 4.49M | +138,439 | +3.18% | 2025-09-30 |
| Lsv Asset Management | $404,270.00 | 2.03% | 3.99M | +124,266 | +3.22% | 2025-09-30 |
| Arrowstreet Capital, Limited Partnership | $314,802.00 | 1.58% | 3.1M | +373,298 | +13.67% | 2025-09-30 |